BioSpace News Archive

Help Therapeutics Co., Ltd. (hereinafter Help Therapeutics) has revealed that the China Center for Drug Evaluation (CDE) has approved the investigational new drug (IND) application of HiCM-188, a human (allogeneic) iPS cell-derived cardiomyocyte therapy in patients with worsening ischemic heart failure.

Valent BioSciences LLC announces its acquisition of FBSciences Holdings, Inc., a leader in the discovery and commercialization of naturally derived plant, soil, and climate health solutions.

Sam Gill to drive growth in evolving sector across Australia and New Zealand

Strategic transaction assembles an experienced management and scientific team world-renowned in mental health treatment, research and development

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), today announced that it will report its Fourth Quarter & Full Year 2022 results on Wednesday, February 22, 2023 after the Mexican Market (BMV) close.

Athersys, Inc. announced today its participation in two upcoming conferences, the International Stroke Conference 2023 (ISC) from February 8-10, 2023 in Houston, TX and BioProcess International US West from February 27-March 2, 2023 in San Diego, CA.

The HealthWell Foundation®, an independent non-profit that provides a financial lifeline for inadequately insured Americans, is proud to announce that it has opened a new fund to provide financial assistance to individuals living with systemic sclerosis with interstitial lung disease (SSc-ILD).

Medline announced a new partnership with Connecticut-based Integrated UVC Solutions to help healthcare providers enhance UV disinfection practices.

Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2023 after the stock market closes on Tuesday, Feb. 28.

Deka Biosciences (“Deka”), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for DK210 (EGFR) and concluded that Deka may proceed with a Phase 1 clinical trial in the United States.